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Introduction
PFAPA Syndrome (Periodic Fever, Aphthous stomatitis,
Pharingitis, and cervical Adenitis) is the most common
periodic fever in childhood; the diagnosis is based on clini-
cal criteria. Familiar Mediterranean Fever (FMF) is a mono-
genic autosomal recessive autoinflammatory disease, whose
diagnosis is based on clinical elements, supported by
MEFV genetic mutations. When there is only a mutation
or no one, the patient undergoes a trial with colchicine for
4-6 months, and diagnosis is confirmed in case of clinical
response and fever early recurrence after suspension.
Current treatment of PFAPA is symptomatic. Febrile epi-
sodes show a rapid response to the administration of one
or two doses of prednisone (1-2 mg/kg) or betamethasone
(0.1-0.2 mg/kg). Total requirement of steroid increases
over time, and the frequency of attacks worsens the quality
of life of patients. In literature, the prophylaxis of PFAPA
febrile attacks with colchicine (0.5-1 mg/day) has been
tested only on a few patients, with controversial results.
Objectives
Considering the similarities between FMF MEFV-negative
patients (MEFVneg) and PFAPA patients, we aimed to
demonstrate that colchicine is effective in PFAPA too:
positive response was evaluated in terms of reduction in
frequency >50% and severity of attacks >50%.
Materials and methods
We conducted a prospective cohort study (from September
2012, still ongoing), comparing two groups: 67 MEFVneg
and 51 PFAPA patients. 36 of the latter group underwent
colchicine trial, after obtaining informed consent.
Results
We assessed the response of PFAPA patients to colchi-
cine preventive treatment: good response was observed
in 75% (27 patients of 36), and a non-response in 25%
(9 pts). The effective treatment rate of MEFVneg is
100%, by definition. The average dose of colchicine
administered in PFAPA was 1.14 mg/day, compared to
MEFVneg (1.34 mg/day). The dose per kilogram of body
weight is 0.020 mg/kg/day in both groups. We can state
that the colchicine dose requirement in PFAPA coincides
to the one of FMF patients.
Conclusion
Our study showed that colchicine regimen is effective in
75% of cases. Prophylaxis with colchicine should be
offered to all PFAPA patients, instead of steroids or other
symptomatic therapy (as paracetamol or ibuprofen),
before the treatment with anti-IL1b biologic drugs, with
considerable savings in pharmacoeconomics.
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